Parabilis Medicines, the developer of drugs and antibody-drug conjugates targeting historically undruggable protein targets and based on stabilized helical peptides or Helicons, has filed for an IPO.

By developing their own functional nerves, these organoids demonstrate how engineering principles can drive biological ...

The Copenhagen-based team is building an AI platform to target underexplored GPCRs to treat diseases once deemed undruggable.

Researchers suggest targeting mTOR activity in aggressive cancers by blocking cholesterol sensing may represent a promising ...

New AI‑designed miniproteins precisely modulate GPCR signaling and reveal a new screening system for targeting receptors long ...

Roughly 2700 attendees heard a range of perspectives from experts in precision medicine, bioinformatics, and rare disease ...

By mapping how genes relate to one another across biological situations, GSFM creates a reference framework that can help ...

Wisconsin Governor Tony Evers (center) leads the ribbon-cutting ceremony at FUJIFILM Cellular Dynamics’ new headquarters and manufacturing facility in Madison, WI. [FUJIFILM Cellular Dynamics] In ...

One of CRS’ first customers is SRTD Biotech, an emerging biotech in Germany, which is starting small scale on novel ...

Biotech companies that use CDD Vault will be able to utilize select Lilly predictive models within their natural scientific ...

New approach recruits the body’s immune system to attack glioblastoma while reducing treatment-related toxicity.

Researchers say epigenetic phase variation mechanism may explain microbiome resilience and variability and could guide the ...